MAO-B inhibitors are still widely used in the management of Parkinson’s and Alzheimer’s diseases and a variety of other psychiatric disorders and continue to be investigated for their therapeutic value and disease-modifying potential [44,45,46,47,48]. The gene discussed is MAOB; the disease is early-onset autosomal dominant Alzheimer disease.